about
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutationsNext-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.Acute myeloid leukemia with translocation t(3;5): new molecular insights.Cooperating gene mutations in acute myeloid leukemia: a review of the literature.Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.TP53 mutation and its prognostic significance in Waldenstrom's Macroglobulinemia.MYD88 L265P mutation in Waldenstrom macroglobulinemia.Copy-number analysis identified new prognostic marker in acute myeloid leukemia.Waved aCGH: to smooth or not to smooth.TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.Absence of CALR mutations in JAK2-negative polycythemia.Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia.Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.Quantification of JAK2V617F mutation by next-generation sequencing technology.Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale.Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.C/EBPA methylation is common in T-ALL but not in M0 AML.Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.Recurrent in-frame insertion in C/EBPα TAD2 region is a polymorphism without prognostic value in AMLComprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: a study of the French Hauts-de-France AML observatoryGenomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patientsMyelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesionsDifferential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemiaMutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemiaWilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemiaAcquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapyMolecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidineMinimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNAImpact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML
P50
Q33572303-21C00350-2813-447B-91C7-17816958B224Q34106837-E2AD8462-732F-41B9-B9F9-1E5452A406E1Q34227693-FD51346A-9669-418F-BFF6-49AAA407E2D8Q34541735-49B2FA1E-61CA-4F9C-994B-9D45ABAAF377Q36356082-FD97DCA1-5575-4EF7-97B8-4DA88CB08207Q36561772-FA4B6989-2BF5-4FEE-9E88-76BF05C15FC7Q36862568-27A72AD0-359C-454C-9D6C-BEF64C5506F1Q37089717-51469748-6270-4C77-BEDC-B282349A0DAEQ38343881-E2DA98E5-3900-497B-A7F4-D403AE1DEEF0Q38650100-233FFB3A-AD72-440C-B0FF-8F15E0AB8A86Q39175169-EC394E89-AE81-48BD-B0FE-30EBABBD1A24Q39337506-FFD09A78-05EC-417B-AD8C-5DAF9A59B086Q39986881-3F62B1A9-F0C2-47EC-9D78-B63C395D0B4AQ40347383-4E80718D-1043-49CF-B3AE-06642849C0DCQ41195432-FCBA4996-201B-4E48-9BD5-2B08915A8AA0Q42334359-74AB1B39-48A1-4485-BD27-3968E9E68D00Q42384356-E1C07514-58D5-4F1C-9384-077C34632B89Q42573844-50FBFE54-B25E-45BB-8217-06FBFFA101C8Q44186784-C0135696-458E-4EEA-A271-70C3B3A27A74Q44671240-38182EE7-FE21-40B2-BBEB-D447DC58E181Q46483697-F3CEA649-B93B-441B-9EE4-2FD371729270Q51215501-B2AAE37B-5897-4961-BF83-AD3A4F8E0401Q51811986-F7113046-F12D-480D-BC25-FF8909092A3EQ53311179-6346D760-527D-4A28-BC89-CC4A73D2CB97Q54210991-8361836D-AE4F-47BE-93DD-00B8877083DBQ55279705-BB476C73-1F6C-49C7-BE46-39E9152A426EQ57605809-876E5EE9-4BE5-4500-A53A-0F8ED203BE9FQ57784507-19104014-3C6F-4676-B266-F6BC0FB5C14BQ60585131-39D59284-EDBD-44E2-970F-8BE2831A2B23Q83421333-6890BE2A-5775-4A91-8B52-5EEF36A09873Q83758438-26E8F61D-EC08-4909-B889-A1ED59701C7BQ84261845-75BDDF71-9CF1-488E-8BEE-43D4FE84DE78Q84562445-74A14AEB-2CD7-489C-A757-832A3920B64EQ84739010-0F5615F1-452B-4186-AFE0-0157F7B183EBQ86729833-2552C342-6EFF-4DA0-AC36-F6BAE3E5D130Q87421398-DD3D79ED-24E3-4757-A97A-41CDEE86E981Q89483800-72972222-6C30-4029-AB07-3B71D62ED2D2
P50
description
researcher ORCID ID = 0000-0003-1909-306X
@en
wetenschapper
@nl
name
O Nibourel
@ast
O Nibourel
@en
O Nibourel
@nl
type
label
O Nibourel
@ast
O Nibourel
@en
O Nibourel
@nl
prefLabel
O Nibourel
@ast
O Nibourel
@en
O Nibourel
@nl
P106
P31
P496
0000-0003-1909-306X